Wealth Enhancement Advisory Services LLC Acquires 5,174 Shares of Ventyx Biosciences, Inc. $VTYX

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 21.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 29,657 shares of the company’s stock after purchasing an additional 5,174 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Ventyx Biosciences were worth $62,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter worth $38,000. Walleye Capital LLC lifted its stake in shares of Ventyx Biosciences by 5.5% in the first quarter. Walleye Capital LLC now owns 504,245 shares of the company’s stock worth $580,000 after buying an additional 26,457 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Ventyx Biosciences in the first quarter worth $56,000. Cerity Partners LLC acquired a new stake in shares of Ventyx Biosciences in the first quarter worth $56,000. Finally, CWM LLC lifted its stake in shares of Ventyx Biosciences by 1,733.8% in the first quarter. CWM LLC now owns 53,088 shares of the company’s stock worth $61,000 after buying an additional 50,193 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

Shares of NASDAQ:VTYX opened at $3.56 on Monday. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $4.05. The company’s fifty day moving average is $2.77 and its 200-day moving average is $2.19. The company has a market capitalization of $253.86 million, a PE ratio of -2.12 and a beta of 1.01.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07. On average, analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.50.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.